Impact of Toxoplasmosis on IL-6 and IL-10 Levels in Cancer Patients Undergoing Chemotherapy

Yassmin Farouk Omar  Omar; Abeer Abbas AL-Attar

doi:10.56286/hs3kj538

Authors

Yassmin Farouk Omar Omar Department of Medical Laboratory Techniques, College of Health and Medical Techniques, Northern Technical University, Kirkuk 36001, Iraq
Abeer Abbas AL-Attar Department of Medical Laboratory Techniques, College of Health and Medical Techniques, Northern Technical University, Kirkuk 36001, Iraq https://orcid.org/0000-0002-4274-5209

DOI:

https://doi.org/10.56286/hs3kj538

Keywords:

Toxoplasmosis, , Chemotherapy, Cytokines, Seroprevalence

Abstract

Toxoplasmosis is a global zoonotic disease, that is mainly asymptomatic in healthy persons, but critical and life-threatening in immunocompromised patients. The infection is caused by an opportunistic obligate intracellular parasite protozoon “Toxoplasma gondii” (T. gondii) that can cause fatal complications in immunosuppressed patients. Cancer patients are being immunocompromised from the cancer itself and the cancer therapy they receive may reactive to a latent T. gondii infection that leaves them at high risk. The combined effect of Toxoplasmosis and cancer on the levels of interleukin-6 (IL-6) and interleukin-10 (IL-10) (important inflammatory cytokines) is complex and varies depending on many factors emphasizing the need for further study in this area. This study aimed to determine the seroprevalence of T. gondii in cancer patients and detect levels of IL-6, IL-10 in those patients to evaluate the differences in cytokines levels and to investigate how toxoplasmosis affects the immune response. 150 blood samples were collected from oncology patients having different types of cancer and receiving chemotherapy, from different ages. And 30 samples from healthy people for control. Samples were collected from the first of October 2023 to the end of March 2024, at Kirkuk oncology and hematology center. The method used was Sandwich-ELISA for detecting levels of Anti-Toxoplasma gondii IgM, IgG, along with IL-6, IL-10 and the results were analyzed statistically. the overall anti-T gondii IgG and IgM seropositive samples were found to be 67 (37.2%) in the study population. Levels of IL-6 and IL-10 were elevated in cancer patients infected with T.gondii. A high seroprevalence rate of T.gondii was detected among cancer patients receiving chemotherapy. A significant elevation in levels of IL-6 and IL-10 was detected in cancer patients associated with infection with T.gondi.

Downloads

Download data is not yet available.

References

Almería S, Dubey J. Foodborne transmission of Toxoplasma gondii infection in the last decade. An overview. Res Vet Sci. 2021 Mar 1;135:371–85.

Sharma J, Rodriguez P, Roy P, Guiton PS. Transcriptional ups and downs: patterns of gene expression in the life cycle of Toxoplasma gondii. Microbes Infect. 2020 Nov 1;22(10):525–33.

Portes J, Barrias E, Travassos R, Attias M, Souza W. Toxoplasma gondii Mechanisms of Entry Into Host Cells. Front Cell Infect Microbiol. 2020 Jun 30;10:294–294.

Calero-Bernall L, Fernández-Escobar M, et al. Unifying Virulence Evaluation in Toxoplasma gondii: A Timely Task. Front Cell Infect Microbiol . 2022 Apr 28 ;12.

Al-Malki E. Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status. Saudi J Biol Sci. 2021 Jan 1;28(1):962–9.

Sinha, S., Sehgal, A., Kaur, U., Sehgal, R. Toxoplasmosis. In: Parija, S.C., Chaudhury, A. (eds) Textbook of Parasitic Zoonoses. Microbial Zoonoses. Springer, Singapore. 2022 Jan 1;93–106.

Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. Journal of cancer research and practice, 2017, 4.4: 127-129.‏

Abdoli A, Barati M, Pirestani M, et al. Screening of toxoplasmosis in cancer patients: a concern. Trop Doct. 2019 Jan 1;49(1):31–4.

Sharma K, Srivastava S, Kundu A, et al. Detection of Antibodies against Toxoplasma from Human Serum Sample using ELISA. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders), 2023, 23.2: 89-91.‏

Holec-Gąsior L, Sołowińska K. IgG Avidity Test as a Tool for Discrimination between Recent and Distant Toxoplasma gondii Infection—Current Status of Studies. Antibodies. 2022 Aug 15;11(3):52–52.

Ali AS, Hachim SK, Saleh ZM. The Role of IL-6 in Inflammatory Reaction during Coronavirus-19 Infection: A Review. J Commun Dis. 2022 Mar 16;210–4.

Gabryšová L, Howes A, Saraiva M, et al. The regulation of IL-10 expression. Interleukin-10 in Health and Disease, 2014, 157-190.‏

O'Brien CA, Batista SJ, Still KM, et al.IL-10 and ICOS Differentially Regulate T Cell Responses in the Brain during Chronic Toxoplasma gondii Infection. J Immunol. 2019 Feb 4;202(6):1755–66.

Araujo WMR, Ayo CM, Previato M, et al. Role of interleukin 1β and interleukin 10 variants on ocular toxoplasmosis in Brazilian individuals. Frontiers in Ophthalmology, 2023, 3: 1183167.‏

Jaffer S, Awad AH. Seroprevalence of Toxoplasma gondii in Immunocompromised cancer patients in Basrah Provence, Southern Iraq. 2022 Dec 30;57–64.

Ali MI, Abd El Wahab WM, Hamdy DA, Hassan A.Toxoplasma gondii in cancer patients receiving chemotherapy: seroprevalence and interferon gamma level. J Parasit Dis. 2019 Mar 30;43(3):464–71.

Bakır A, Guney M. Evaluation of Toxoplasma gondii IgM and IgG Seropositivities in Serum Samples Sent from Pediatric and Adult Hematology/Oncology Outpatient Clinics. Med Lab Technol. 2020 Nov 29;6(2):163–71.

Guan Y bin, Sun X xiao, Chen S lian, Zhu X ting, Zeng Z hua, Lu H wei, et al. Seroprevalence of Toxoplasma gondii infection among patients of a tertiary hospital in Guangzhou, Guangdong province, PR China. PLOS ONE. 2023 Jul 10;18(7):e0286430.

Abid Mohammed K. Levels of Interleukin-6,17, Complement and Dopamine in Infected Women with Toxoplasmosis. South Asian Res J Pharm Sci. 2022 Jun 6;4:54–9.

Rose-John S. Interleukin-6 signalling in health and disease. F1000Research. 2020 Aug 20;9:F1000 Faculty Rev-1013.

Kays JK, Koniaris LG, Cooper CA, Pili R, Jiang G, Liu Y, et al. The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma. Cancers. 2020 Jun;12(6):1605.

Shimura Y, Kurosawa H, Tsuchiya M, Sawa M, Kaneko H, Liu L, et al. Serum interleukin 6 levels are associated with depressive state of the patients with knee osteoarthritis irrespective of disease severity. Clin Rheumatol. 2017 Dec 1;36(12):2781–7.

Keaton SA, Madaj ZB, Heilman P, Smart L, Grit J, Gibbons R, et al. An inflammatory profile linked to increased suicide risk. J Affect Disord. 2019 Mar 15;247:57–65.

Belhimeur S, Briquet S, Peronet R, Pham J, et al. Plasmodium-encoded murine IL-6 impairs liver stage infection and elicits long-lasting sterilizing immunity. Frontiers in Immunology, 2023, 14: 1143012.‏

xiu, kian. “Understanding the Role of Inflammation in Cancer Development and Progression.” OSF Preprints, 5 June 2023.

Ali BAM, Hamza DM, AL-Attabbi AS. Study levels of PDL-1, IL-10 and TGF-β in Patients with Toxoplasmosis. Ann Romanian Soc Cell Biol. 2021 Mar 22;1899–913.

Carlini V, Noonan DM, Abdalalem E,‏ et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Frontiers in immunology, 2023, 14: 1161067.‏